Liver cancer screening in a high-risk population in China fails to reduce mortality

Sammy Saab MD, MPH (Commentary Author)
{"title":"Liver cancer screening in a high-risk population in China fails to reduce mortality","authors":"Sammy Saab MD, MPH (Commentary Author)","doi":"10.1016/j.ehbc.2004.05.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Question</h3><p>Does liver cancer screening reduce mortality from the disease in a high-risk Chinese population?</p></div><div><h3>Study design</h3><p>Cluster randomised controlled trial.</p></div><div><h3>Main results</h3><p>In people at high risk of liver cancer, screening did not significantly reduce the incidence of primary liver cancer or risk of death compared with no screening (see Table 1), despite earlier detection of the disease (see notes).<span><div><div><table><tbody><tr><td>Table 1 Primary liver cancer incidence and mortality rates in a high-risk Chinese population.</td></tr><tr><td></td><td>Screened (<span><math><mtext>N=3712</mtext></math></span>)</td><td>Not screened (<span><math><mtext>N=1869</mtext></math></span>)</td><td><span><math><mtext>p</mtext></math></span> value</td></tr><tr><td>Number of primary liver cancer cases</td><td>257 (7%)</td><td>117 (6%)</td><td></td></tr><tr><td>Incidence rate<sup>†</sup></td><td>1341</td><td>1195</td><td>0.30</td></tr><tr><td>Deaths from primary liver cancer</td><td>218 (6%)</td><td>109 (6%)</td><td></td></tr><tr><td>Mortality rate<sup>†</sup></td><td>1138</td><td>1113</td><td>0.86</td></tr></tbody></table></div></div></span> <sup>†</sup>Per 100,000 person years.</p></div><div><h3>Authors’ conclusions</h3><p>Liver cancer screening in a high-risk population in China does not reduce mortality from the disease.</p></div>","PeriodicalId":100512,"journal":{"name":"Evidence-based Healthcare","volume":"8 4","pages":"Pages 221-223"},"PeriodicalIF":0.0000,"publicationDate":"2004-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ehbc.2004.05.003","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence-based Healthcare","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S146294100400083X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Question

Does liver cancer screening reduce mortality from the disease in a high-risk Chinese population?

Study design

Cluster randomised controlled trial.

Main results

In people at high risk of liver cancer, screening did not significantly reduce the incidence of primary liver cancer or risk of death compared with no screening (see Table 1), despite earlier detection of the disease (see notes).

Table 1 Primary liver cancer incidence and mortality rates in a high-risk Chinese population.
Screened (N=3712)Not screened (N=1869)p value
Number of primary liver cancer cases257 (7%)117 (6%)
Incidence rate134111950.30
Deaths from primary liver cancer218 (6%)109 (6%)
Mortality rate113811130.86
Per 100,000 person years.

Authors’ conclusions

Liver cancer screening in a high-risk population in China does not reduce mortality from the disease.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在中国的高危人群中进行肝癌筛查未能降低死亡率
问题癌症筛查是否能降低中国高危人群的肝癌死亡率?研究设计聚类随机对照试验。主要结果在癌症高危人群中,尽管早期发现了原发性肝癌(见注释),但与未进行筛查相比,筛查并没有显著降低原发性癌症的发病率或死亡风险(见表1)。表1高危中国人群原发性肝癌癌症发病率和死亡率。筛查(N=3712)未筛查(N=1869)p值原发性癌症病例数257(7%)117(6%)发病率†134111950.30原发性肝癌死亡218(6%)109(6%)死亡率†113811130.86†/10万人年。作者的结论:在中国高危人群中进行肝癌筛查并不能降低该疾病的死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
High-quality nutrition counselling for hypercholesterolemia by public health nurses in rural areas does not affect total blood cholesterol No association between mobile phone usage and development of acoustic neuroma Retaplase plus abciximab improves non-fatal outcomes, but not overall survival in people with diabetes and acute ST-segment elevation myocardial infarction Intravenous magnesium sulphate does not improve survival or disability outcomes in people with stroke Rate of major complications is higher in laparoscopic than abdominal hysterectomy but quality of life improves with both procedures
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1